Structure

InChI Key HIFJCPQKFCZDDL-ACWOEMLNSA-N
Smiles CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O
InChI
InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H32O4
Molecular Weight 360.49
AlogP 3.54
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 8.0
Polar Surface Area 77.76
Molecular species ACID
Aromatic Rings 0.0
Heavy Atoms 26.0

Bioactivity

Mechanism of Action Action Reference
Prostanoid IP receptor agonist AGONIST ISBN DailyMed
Protein: Prostanoid IP receptor

Description: Prostacyclin receptor

Organism : Homo sapiens

P43119 ENSG00000160013
Assay Description Organism Bioactivity Reference
In vitro inhibition of ADP (0.5 x 10E-9 M)-induced platelet aggregation in human PRP Homo sapiens 0.82 nM
In vitro inhibition of collagen (0.66 ug/mL)-induced platelet aggregation in human PRP Homo sapiens 0.39 nM
In vitro inhibition of thrombin (0.14 IU/mL)-induced platelet aggregation in human PRP Homo sapiens 0.39 nM
Inhibitory activity against ADP-induced platelet aggregation using human platelet rich plasma at a concentration of 4 uM by functional assay Homo sapiens 1.4 nM
Inhibitory concentration for displacing [3H]iloprost from human platelet membrane at 5.4 nM at 37 degree C Homo sapiens 47.7 nM
Compound was tested for inhibition of blood platelet aggregation induced by ADP; 0.2-0.5*10e-9 Homo sapiens 0.2 nM
In vitro inhibition of 5.86 uM ADP-induced human platelet aggregation in platelet rich plasma (PRP) Homo sapiens 2.0 nM
In vitro inhibition of ADP-induced platelet aggregation using human platelet rich plasma Homo sapiens 2.5 nM
PGI-2 agonistic activity by measuring inhibition of 4 uM ADP-induced human platelet aggregation Homo sapiens 1.4 nM
Prostaglandin I2 receptor binding by displacement of [3H]iloprost from human platelets Homo sapiens 27.0 nM
Displacement of [3H]iloprost from Prostaglandin I2 receptor of human platelets Homo sapiens 27.0 nM
In vitro Prostacyclin (PGI-2) receptor binding assay was determined based on displacement of [3H]iloprost radioligand from cloned human IP receptor None 6.5 nM
In vitro inhibition of ADP (1.25 x 10E-6 M)-induced platelet aggregation in rat PRP (wistar) Rattus norvegicus 11.4 nM
In vitro inhibition of ADP-induced aggregation of human platelets Homo sapiens 2.0 nM
Ability to inhibit binding of [3H]iloprost to cloned human prostaglandin I2 receptor Homo sapiens 6.5 nM
In vitro inhibition of ADP-induced platelet aggregation in human platelet rich plasma Homo sapiens 2.5 nM
Inhibition concentration against ADP-induced platelet aggregation using human platelet rich plasma Homo sapiens 2.5 nM
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma Homo sapiens 5.0 nM
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma Homo sapiens 5.0 nM
Displacement of radiolabeled iloprost from human prostanoid IP receptor Homo sapiens 7.3 nM Displacement of radiolabeled iloprost from human prostanoid IP receptor Homo sapiens 17.0 nM
Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control Mus musculus 55.0 %
Binding affinity to PGI2 receptor (unknown origin) by radioligand displacement assay Homo sapiens 13.0 nM
Binding affinity to human PGI2 receptor by radioligand displacement assay Homo sapiens 4.8 nM Binding affinity to human PGI2 receptor by radioligand displacement assay Homo sapiens 8.4 nM
Displacement of [3H]iloprost from human recombinant Prostanoid IP receptor expressed in HEK293 cells Homo sapiens 10.0 nM
Displacement of [3H]iloprost from human recombinant IP receptor expressed in HEK293 cells measured after 60 mins by scintillation counting method Homo sapiens 10.0 nM
Agonist activity at recombinant rat IP receptor expressed in CHO-K1 cells assessed as increase in intracellular cAMP level after 1 hr incubation by HTRF method Rattus norvegicus 0.69 nM
Agonist activity at recombinant human IP receptor expressed in CHO-K1 cells assessed as increase in intracellular cAMP level after 1 hr incubation by HTRF method Homo sapiens 2.4 nM
Agonist activity at recombinant human DP1 receptor expressed in CHO-K1 cells assessed as increase in intracellular cAMP level after 1 hr incubation by HTRF method Homo sapiens 147.0 nM
Agonist activity at IP receptor in human primary platelets assessed as inhibition of ADP-induced platelet aggregation Homo sapiens 9.0 nM
Displacement of [3H]-iloprost from recombinant human IP receptor expressed in CHO-K1 cell membranes incubated for 1 hr by top count scintillation counting method Homo sapiens 3.2 nM
Displacement of [3H]-iloprost from recombinant rat IP receptor expressed in CHO-K1 cell membranes incubated for 1 hr by top count scintillation counting method Rattus norvegicus 1.0 nM
Displacement of [3H]-iloprost from recombinant dog IP receptor expressed in CHO-K1 cell membranes incubated for 1 hr by top count scintillation counting method Canis lupus familiaris 1.7 nM
Displacement of [3H]-iloprost from recombinant monkey IP receptor expressed in CHO-K1 cell membranes incubated for 1 hr by top count scintillation counting method Macaca mulatta 1.6 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 1.51 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 17.06 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.17 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.17 %

Cross References

Resources Reference
ChEBI 63916
ChEMBL CHEMBL494
DrugBank DB01088
DrugCentral 1422
FDA SRS JED5K35YGL
Guide to Pharmacology 1895
KEGG D02721
PubChem 5311181
SureChEMBL SCHEMBL6083382
ZINC ZINC13587680